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Survivin is a protein which functions as a mitotic regulator as well as apoptosis inhibitor. In this
study, we show that introduction of synthetic miR-542-3p mimetic reduced both mRNA and protein
levels of survivin. In A549 cells, luciferase reporter assay revealed that miR-542-3p targeted pre-
dicted binding sites in the 30-untranslated region (30-UTR) of survivin. We also demonstrate that
ectopic expression of miR-542-3p inhibited cell proliferation by inducing Gap 1 (G1) and Gap 2/Mito-
sis (G2/M) cell cycle arrest. Collectively, these results suggest that survivin is a direct target of miR-
542-3p and growth inhibition by miR-542-3p may have a potential utility as an anti-cancer therapy.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are small endogenous RNAs which regu-
late gene expression at the post-transcriptional level [1,2]. Accu-
mulating evidence indicates that miRNAs play important roles in
many cellular processes including proliferation, apoptosis, and dif-
ferentiation. Recently, several studies showed that miRNAs affect
cell proliferation by controlling cell cycle-related genes. For in-
stances, miR-221 and -222 target cyclin-dependent kinase (CDK)
inhibitor p27Kip1 and p57Kip2 [3,4]. Up-regulation of those miR-
NAs in several cancers facilitated cell proliferation by negatively
regulating CDK inhibitors. Another CDK inhibitor p21Cip1 was a di-
rect target of miR-106b and ectopic expression of miR-106b re-
sulted in enhanced cell proliferation by facilitating Gap 1 (G1)/S
progression [5,6]. miR-34a is transcriptionally activated by tumor
suppressor p53 and functions as a downstream mediator by
down-regulating several cell cycle genes including CDK4, CDK6, cy-
clin D1, cyclin E2, and E2 promoter binding factor 3 [7,8]. miR-16
also regulates multiple cell cycle genes including cyclin D1, cyclin
D3, cyclin E1, and CDK6 and introduction of miR-16 into A549 cells
induced G1 arrest [9,10].chemical Societies. Published by E
M, Gap 2/Mitosis; 30-UTR, 30-
E2F3, E2 promoter binding
al passenger complex; rRNA,Survivin belongs to a family of the inhibitor of apoptosis pro-
tein. In addition to its function as a negative regulator of apoptosis,
survivin plays an important role in controlling cell division as a
multi-protein complex called the chromosomal passenger complex
[11]. Survivin has been an ideal target for anti-cancer therapy since
survivin is upregulated in many cancers whereas its expression is
low in normal tissues [12] and targeting survivin leads to inhibi-
tion of its dual functions, i.e., inhibition of apoptosis and regulation
of cell division [13,14]. Recently, it was reported that miRNAs reg-
ulated survivin signaling [15,16]. For example, miR-27a regulates
the zinc ﬁnger ZBTB10 gene, a putative Sp repressor. Down-regula-
tion of ZBTB10 gene by miR-27a results in up-regulation of Sp1,
Sp3, and Sp4 proteins and several Sp-dependent genes including
survivin [15].
In this study, we show that survivin is a direct target of miR-
542-3p as revealed by Western blot, real-time PCR and luciferase
reporter analyses. Ectopic expression of miR-542-3p caused cell
cycle arrest at both G1 and Gap 2/Mitosis (G2/M) phases. Thus,
miR-542-3p appears to be a cell cycle regulator and may have po-
tential for the treatment of cancer.
2. Materials and methods
2.1. RNA oligonucleotides
MicroRNA mimic and a negative control (NC; CN-001000-01)
were purchased from Dharmacon (Lafayette, CO). Survivin siRNAlsevier B.V. All rights reserved.
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mimics were resuspended in DEPC-treated water to a ﬁnal concen-
tration of 20 lM.
2.2. Cell lines and transfection
Human cell lines A549 (human epithelial, lung carcinoma de-
rived; KCLB 10 185), HeLa (human epithelial, cervix adenocarci-
noma derived, KCLB 10 002), and MCF7 (human epithelial, breast
adenocarcinoma derived, KCLB 30 022) were obtained from Korean
Cell Line Bank (Seoul, Korea). Cells were cultured in RPMI-1640
supplemented with 10% fetal bovine serum, 100 U/ml penicillin
and 100 lg/ml streptomycin and maintained at 37 C in a humid-
iﬁed 5% CO2 incubator. Transfection was carried out using Lipofect-
amine RNAiMAX (Invitrogen) as described previously [18]. After
incubation with a transfection solution for 5 h, cells were cultured
at 37 C in standard culture media for different times before har-
vested for Western blot and other experiments.
2.3. Western blot analysis
Western blot analysis was performed as described previously
[18]. Primary antibody speciﬁc for survivin (#2803) was obtained
from Cell Signaling Technology (Danvers, MA). Anti-b-actin (C-
11) antibody, which was used to monitor equal loading of protein
samples, was purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
2.4. Quantitative real-time PCR analysis
Real-time PCR reactions were performed in 96-well plates using
ABI 7900 HT system (Applied Biosystems, Foster City, CA). Each PCR
reaction mixture (20 ll) contained 10 ll of 2X SYBR Green Master
Mix (Applied Biosystems) and 0.8 ll of forward and reverse primers
(10 pmol/ll). The cycling conditionswere as follow: initial denatur-
ation at 95 C for 10 min, followed by 40 PCR cycles of 95 C for 30 s,
55 C for 30 s and 72 C for 30 s. The sequences of the primers spe-
ciﬁc for survivin were: forward primer, 50-GCACCACTTCCAGGGTT-
TAT-30; reverse primer, 50-CTCTGGTGCCACTTTCAAGA-30. The
amount of survivin transcript was divided by that of GAPDH as a
means to obtain normalized expression levels. To quantitate the
amount of 18S ribosomal RNA (rRNA), a plasmid DNA containing
the sequence between 873 and 1398 nt of 18S rRNA gene was used
to construct a standard curve. The DNA concentration was deter-
mined by optical density measurement and tenfold serial dilutions
were used to generate the standard curve of 18S rRNA. The primers
for 18S rRNA had the following sequences: forward primer, 50-CG
CCGCTAGAGGTGAAATTC-30; reverse primer, 50-TTGGCAAATGCTTT
CGCTC-30. The amount of 18S rRNA was obtained by calculating
the absolute 18S rRNA concentration using the standard curve.
2.5. Cell proliferation assay
For cell proliferation assay, 1.8  104 A549 cells were seeded on
24-well plates and next day, cells were transfected with miRNA
mimics (20 nM). At 72 h after transfection, the cell proliferation
was measured using Cell Counting Kit-8 (CCK-8; Dojindo, Kuma-
moto, Japan) according to manufacturer’s protocol. Brieﬂy, 1/10
volume of CCK-8 solution was added to each well and incubated
for 1 h at 37 C. The plates were read in a microplate reader (model
550; Bio-Rad Laboratories, Hercules, CA) at 450 nm.
2.6. Colony formation assay
One day before transfection, 8  104 A549 cells were seeded in
12-well plates. Next day, cells were transfected with 20 nMmiRNAmimics. Twenty-four hours after transfection, 200 cells were
seeded in 6-well plates and cultured for 10 days in RPMI-1640
media. Colonies were then ﬁxed with methanol and stained with
0.5% crystal violet in 25% methanol for 10 min at room tempera-
ture. Total number of colonies per 6-well were counted in triplicate
for each sample.
2.7. Construction of 30-untranslated region (30-UTR) reporter plasmids
and luciferase assay
The full-length cDNA clone containing the 30-UTR of survivin
gene (NM_001168) was obtained from Open Biosystems (Hunts-
ville, AL). The sequence between 551 and 1670 nt was ampliﬁed
using primers Surv-551L and Surv-1670R and cloned into XhoI/
NotI sites of psiCHECK-2 vector (Promega) to give rise to pSurv-
30-UTR plasmid. To delete three predicted target site of miR-542-
3p from pSurv-30-UTR plasmid, PCR approach was used as
described previously [18]. Brieﬂy, to delete 50-most target site, DNA
fragments containing 379 bp upstream and 719 bp downstream
of the target site were ampliﬁed using primers Surv-551L/929R
and Surv-952L/1670R, respectively. The ampliﬁed DNA fragments
were digested with XbaI, ligated at 4 C overnight, digested with
XhoI and NotI, and then cloned into psiCHECK-2 vector. Similar
cloning strategy was used to delete two other target sites using
primers 992R/1015L and 1461R/1484L, respectively. Primer se-
quences were as follow: Surv-551L; 50-GATCTCGAGGGCCTCTGGCC
GGAGCTGCCTGG-30, Surv-1670R; 50-GATGCGGCCGCTCAGGAACA
GCCGAGATGACCT-30, 929R; 50-CATTCTAGAGGTCCAGACACATTCAC
TGTGG-30, 952L; 50- CATTCTAGAGTCCTGAGTGTGGACTTGGCAG-30,
992R; 50-CATAAGCTTGCTCAGATTCAACAGGCACCTG-30, 1015L; 50-
CATAAGCTTCCTGTGCCTCCTCAGAGGACAG-30, 1461R; 50-CATGAAT
TCCTGACAGACACACGGCCTGCAG-30, 1484L; 50-CATGAATTCTTCT
CCACACGGGGGAGAGACG-30. For luciferase assay, 8  104 A549
cells in 12-well plate was cotransfected with 250 ng of luciferase
vector and miRNA mimics (10 nM) using Lipofectamine 2000
(Invitrogen). At 48 h after transfection, ﬁreﬂy and Renilla luciferase
activities were measured using Dual-luciferase assay (Promega)
following the manufacturer’s protocol.
2.8. Microarray experiments
Microarray analysis was performed using the Illumina Human
Ref-8 bead array (Illumina, Inc., San Diego, CA) as described previ-
ously [18]. The array was scanned with an Illumina BeadArray
Reader and Data analysis was performed using the Illumina Bead-
Studio program.
2.9. Cell cycle analysis
Cells were harvested at 72 h after transfection. After ﬁxing at
70% ethanol, cells were treated with RNase A (1 mg/ml) for
30 min and then, stained with propidium iodide (50 lg/ml). DNA
content was analyzed using FACS Vantage SE ﬂow cytometer (Bec-
ton Dickinson, Franklin, NJ). For mitotic arrest, A549 cells were
treated with 100 ng/ml of nocodazole (Sigma, St Louis, MO) 48 h
post-transfection and subjected to FACS analysis after 16 h noco-
dazole treatment.
3. Results and discussion
3.1. Target identiﬁcation using microarray analyses
Recently, we found that several miRNAs including miR-542-3p
targeted 30-UTR of cyclooxygenase-2 in luciferase reporter assay.
Since little is known about functional aspects of miR-542-3p, we
have chosen this miRNA for further analyses. Since a miRNA con-
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yses to identify additional target(s) of miR-542-3p [19]. In addition
to translation repression, miRNAs cause target mRNA degradation
and these changes in mRNA level can be detected by microarray
experiments [20]. Compared to NC-transfected cells, 431 tran-
scripts and 340 transcripts were down- and up-regulated by two-
fold or greater in cells transfected with miR-542-3p, respectively.
Among 431 down-regulated transcripts, 184 transcripts were pre-
dicted to be a target of miR-542-3p by TargetScan including evolu-
tionary non-conserved target genes whereas only 21 transcripts
were predicted among 340 up-regulated genes, indicating that
down-regulated transcripts are enriched for a predicted target of
miR-542-3p. Of note, the most down-regulated candidate gene
was survivin, whose expression was decreased by 17.99-fold. As
predicted by TargetScan, there were three binding sites for miR-
542-3p in the 30-UTR of survivin, whose location is schematically
represented in Fig. 1A. In Supplementary Table 1, top-ranked 20
candidate genes predicted by TargetScan were displayed according
to signiﬁcantly decreased expression in miR-542-3p-transfected
cells compared to NC-transfected cells.
3.2. Survivin is a direct target of miR-542-3p
To validate survivin as a target of miR-542-3p, down-regulation
of survivin at the mRNA and protein levels was examined by real-
time PCR and Western blot analyses. As can be seen in Fig. 1B,
survivin mRNA in miR-542-3p-transfected cells was signiﬁcantly
decreased compared to NC-transfected cells (16%). In Western
blot analysis (Fig. 1C), very little survivin was detected in both
A549 and HeLa cells transfected with miR-542-3p, thus indicating
that miR-542-3p down-regulates endogenous survivin at both the
mRNA and protein levels.Fig. 1. Down-regulation of survivin by miR-542-3p at mRNA and protein levels via direc
miR-542-3p predicted by TargetScan in the 30-UTR of survivin. Numbers in parentheses
with miR-542-3p and NC mimetics (20 nM), cells were subjected to real-time PCR (B) an
cells was expressed as the percentage of that in NC-transfected cells, which was set a
***P < 0.05. (D) Direct targeting of survivin 30-UTR by miR-542-3p. A549 cells were cotr
survivin. At 48 h after transfection, luciferase activity was measured using dual-luciferase
was set at 100%. In (D), the experiments were performed in triplicate and repeated th
mutated at S3; M1,2, mutated at S1 and S2; M1,3, mutated at S1 and S3; M2,3, mutatedTo demonstrate direct interaction between miR-542-3p and 30-
UTR of survivin, miR-542-3p was cotransfected with luciferase re-
porter plasmid bearing 30-UTR of survivin. As can be seen in Fig. 1D,
cotransfection with miR-542-3p resulted in signiﬁcant decrease in
luciferase activity compared to that in NC-transfected cells. To ver-
ify that miR-542-3p interacts with predicted binding sites in 30-
UTR of survivin, all three predicted binding sites for miR-542-3p
as predicted by TargetScan were deleted from survivin 30-UTR
using PCR approach and the resulting luciferase reporter plasmid
was cotransfected with miR-542-3p. As shown in Fig. 1D, luciferase
activity was not decreased when three predicted binding sites are
deleted, indicating speciﬁcity of this interaction. To identify which
sites are functional, 2 sites out of 3 predicted binding sites were de-
leted to construct reporter plasmids containing only one intact site.
As can be seen in Fig. 1D, when site 1 (M2,3) or 3 (M1,2) is intact,
luciferase activity was not decreased. However, when site 2 (M1,3)
is intact, luciferase activity was signiﬁcantly decreased, suggesting
that site 2 is functional. Same results were obtained with cotrans-
fection of mutant plasmids containing two intact sites and miRNA
mimics: when site 2 (M2) is deleted, only a slight decrease in lucif-
erase activity was observed whereas luciferase activity was signif-
icantly decrease when site 1 (M1) or site 3 (M3) is deleted,
indicating that site 2 functions as a major site for post-transcrip-
tional repression of survivin expression by miR-542-3p. Taken to-
gether, these data indicate that miR-542-3p directly regulate
survivin mainly through interaction with predicted binding site 2
in the 30-UTR of survivin.
3.3. Growth inhibition by miR-542-3p
Since miR-542-3p targets survivin which plays an important
role in cell division, we have examined the effects of miR-542-3pt targeting of 30-UTR. (A) A schematic diagram of 3 binding sites (S1, S2, and S3) for
represent the nucleotide position in survivin gene. (B, C) At 48 h after transfection
d Western blot (C) analyses. In (B), survivin mRNA level of miR-542-3p-transfected
t 100%. The experiments in (B) were performed in triplicate and repeated twice.
ansfected with miRNA (10 nM) and luciferase reporter plasmids carrying 30-UTR of
assays (Promega). Normalized Renilla luciferase activity in cells transfected with NC
rice. *P < 0.001, **P < 0.01, ***P < 0.05. M1, mutated at S1; M2, mutated at S2; M3,
at S2 and S3; M1,2,3, mutated at S1, S2, and S3.
Fig. 2. Inhibitory effects of miR-542-3p on cell proliferation and colony formation. (A) Cell proliferation assay by CCK-8. A549, HeLa, and MCF7 cells were transfected with
miR-542-3p (20 nM). NC and survivin siRNA were used as the negative and positive controls, respectively. At 72 h after transfection, cell growth was measured using CCK-8
following manufacturer’s instruction. In (A), the experiments were performed in triplicate and repeated twice. *P < 0.001. (B) Colony formation assay to determine growth
inhibition by miR-542-3p. At 24 h after transfection, A549 cells were harvested and 200 transfected cells were plated on each well of 6-well plates. After culturing for 10 days,
the number of stained colonies was counted to measure cell proliferation. The relative cell growth is shown after setting the number of colonies formed from cells transfected
with NC mimetic to 100%. In (B), the experiments were performed in triplicate and repeated twice. *P < 0.001. On the right side of Fig. 2B, the photograph showed 6-wells
containing colonies grown from cells transfected with NC or miR-542-3p.
Fig. 3. G1 and G2/M arrest by miR-542-3p. A549 cells were transfected with miR-542-3p and NC mimetics (20 nM). With (B) or without (A) nocodazole treatment,
transfected cells were stained with propidium iodide and analyzed with ﬂow cytometer. Si-survivin; survivin siRNA.
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mation assays. As shown in Fig. 2A, transfection of miR-542-3p
into several cell lines signiﬁcantly inhibited cell proliferation in
all tested cell lines by CCK-8 assay. When transfected with survivin
siRNA, similar level of inhibition was observed in A549 cells when
compared to miR-542-3p. In colony formation assay, ectopic
expression of miR-542-3p in A549 cells resulted in signiﬁcant inhi-
bition of colony formation compared to NC-transfected cells
(Fig. 2B). Taken together, these results indicate that miR-542-3p
has an adverse effect on cell proliferation.
3.4. miR-542-3p induces G1 and G2/M cell cycle arrest
To determine which stage of cell cycle is arrested during cell cy-
cle distribution, we examined DNA content by ﬂow cytometry after
staining with propidium iodide. As can be seen in Fig. 3A, the per-
centage of miR-542-3p-transfected cells at the S phase was de-creased while that of miR-542-3p-transfected cells at the G2/M
phase was increased compared to NC-transfected cells. When trea-
ted with survivin siRNA, however, much more cells were accumu-
lated in G2/M phase than miR-542-3p-transfected cells in which
survivin is also down-regulated. One possibility for the discrepancy
was that miR-542-3p also induces G1 arrest in addition to G2/M
arrest. To test the possibility, cells were treated with nocodazole,
a microtubule destabilizer, which arrests at G2/M phase. In NC-
transfected cells, nocodazole treatment resulted in substantial ar-
rest in G2/M phase (Fig. 3B). However, signiﬁcant number of
miR-542-3p-transfected cells remained in G1 phase even in the
treatment of nocodazole. These results indicate that in addition
to G2/M arrest, miR-542-3p also induces G1 arrest, which may
be mediated through down-regulation of unidentiﬁed target(s)
by miR-542-3p.
Thus, like miR-34 and miR-16, miR-542-3p seems to coordi-
nately regulate cell proliferation by down-regulating multiple cell
Fig. 4. miR-542-3p down-regulates 18S rRNA. A549 cells were transfected with
miR-542-3p and NC mimetics (20 nM) and at 48 h after transfection, total RNA was
prepared and subjected to denaturing gel electrophoresis on Agilent 2100 Bioan-
alyzer (Agilent Technologies, CA) (A) and quantitative real-time PCR (B). In (B), the
amount of 18S rRNA in NC-transfected cells was set at 100%. The experiments in (B)
were performed in triplicate and repeated twice. **P < 0.01.
4052 S. Yoon et al. / FEBS Letters 584 (2010) 4048–4052cycle-related genes. When examining microarray data, potential
candidate targets include CDK6 at G1/S phase and TUBB2B at G2/
M phase. Additionally, when examining RNA quality in microarray
experiments, we found that 18S rRNA was signiﬁcantly decreased
in cells transfected with miR-542-3p compared to NC-transfected
cells (Fig. 4A). To measure the amount of 18S rRNA in miR-542-
3p-transfected cells compared with that in NC-transfected cells,
we have performed quantitative real-time PCR. The result showed
that the level of 18S rRNA in miR-542-3p-transfected cells was de-
creased to 70% of that in NC-transfected cells (Fig. 4B). Since rRNAs
play crucial roles in the process of protein synthesis, it is possible
that reduction in 18S rRNA may affect cell proliferation. Consider-
ing miRNA target(s), miR-542-3p may decrease 18S rRNA directly
or indirectly by targeting other gene(s) whose down-regulation
in turn affects 18S rRNA.
miR-542-3p regulates cell cycle by inducing both G1 and G2/M
arrests. At G2/M phase, growth inhibition was, at least in part,
mediated by down-regulation of survivin which is an attractive
target for anti-cancer therapy. Thus, on the therapeutic side,
miR-542-3p has the potential for the application in the treatment
of cancers. In the future, identiﬁcation of more targets of
miR-542-3p, especially target(s) responsible for G1 arrest, may
be necessary to gain more insight into the functional signiﬁcance
of miR-542-3p as a regulator of cell cycle progression.
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